PCM
REGN icon

Pavaki Capital Management’s Regeneron Pharmaceuticals REGN Stock Holding History

Pavaki Capital Management’s Portfolio REGN Stock Details REGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$6.17M Buy
9,900
+2,000
+25% +$1.36M 2.15% 10
2026
Q1 		$6.1M Sell
7,900
-11,500
-59% -$8.8M 2.59% 7
2025
Q4 		$15M Buy
+19,400
New +$13.2M 5.87% 4

Other funds holding REGN

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Dodge & Cox
Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Nuveen
Nuveen Charlotte, North Carolina $419B AUM 43.02% 1-Year Est. Return

Pavaki Capital Management's REGN Position: Q2 2026 in Review

Pavaki Capital Management increased its Regeneron Pharmaceuticals (REGN) stake by 25% in Q2 2026, buying an estimated $1.36M and bringing the position to 9,900 shares worth $6.17M. The position accounts for 2.15% of the portfolio, ranked #10.

Pavaki Capital Management first reported a position in REGN in Q4 2025 and has held it in 3 quarters since. The position peaked at $15M in Q4 2025. 1,256 funds tracked by Wall St. Rank hold REGN as of Q2 2026.

  • Pavaki Capital Management held 9,900 shares of Regeneron Pharmaceuticals worth $6.17M as of Q2 2026.
  • Pavaki Capital Management bought 2,000 Regeneron Pharmaceuticals shares in Q2 2026, an estimated $1.36M.
  • Regeneron Pharmaceuticals made up 2.15% of Pavaki Capital Management's portfolio in Q2 2026, its #10 holding.
  • Pavaki Capital Management first reported a position in Regeneron Pharmaceuticals in Q4 2025 and has held it in 3 quarters since.
  • Pavaki Capital Management's Regeneron Pharmaceuticals position peaked at $15M in Q4 2025.
  • 1,256 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q2 2026.

Based on Pavaki Capital Management's 13F filing for Q2 2026, filed 7 Aug 2026.